Interleukin for GVHD – pro
Interleukin has been studied in an observational setup by J. Koreth with apparently beneficial results in patients with GVHD who failed steroids. This built on a number of prior studies of the concept, but those studies did not involve larger numbers of patients and they were nto clicnially designed to evaluate therapy. A recent review by FLowers in 2015 mentiones but does not recommend this treatment. There does nto apepar to be sufficeint credible literature to recommend its clinical use.
John Koreth, M.B., B.S., D.Phil., Ken-ichi Matsuoka, M.D., Ph.D., Haesook T. Kim, Ph.D., Sean M. McDonough, M.S., Bhavjot Bindra, B.S., Edwin P. Alyea, III, M.D., Philippe Armand, M.D., Ph.D., Corey Cutler, M.D., M.P.H., Vincent T. Ho, M.D., Nathaniel S. Treister, D.M.D., D.M.Sc., Don C. Bienfang, M.D., Sashank Prasad, M.D., Dmitrios Tzachanis, M.D., Ph.D., Robin M. Joyce, M.D., David E. Avigan, M.D., Joseph H. Antin, M.D., Jerome Ritz, M.D., and Robert J. Soiffer, M.D. Interleukin-2 and Regulatory T Cells in Graft-versus-Host DiseaseN Engl J Med 2011; 365:2055-2066
Ken-ichi Matsuoka et al, Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host DiseaseScience Translational Medicine 03 Apr 2013:Vol. 5, Issue 179, pp. 179ra43
M. Flowers et al, How we treat chronic graft-versus-host disease, January 22, 2015; Blood: 125 (4)